Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models
Abstract Nirmatrelvir (PF-07321332; NMV) the antiviral component of PAXLOVID™ is a
potent and selective inhibitor of the SARS-CoV-2 main protease (M pro), which plays a
critical role in viral replication. PAXLOVID, comprised of nirmatrelvir and ritonavir (used as a
pharmacokinetic enhancer), is an oral therapy currently in development as a therapeutic
option for those infected with SARS-CoV-2 to prevent progression to severe disease,
hospitalization, and death. PAXLOVID has been shown to be efficacious against …
potent and selective inhibitor of the SARS-CoV-2 main protease (M pro), which plays a
critical role in viral replication. PAXLOVID, comprised of nirmatrelvir and ritonavir (used as a
pharmacokinetic enhancer), is an oral therapy currently in development as a therapeutic
option for those infected with SARS-CoV-2 to prevent progression to severe disease,
hospitalization, and death. PAXLOVID has been shown to be efficacious against …